Diagnostic performance of plasma GFAP in preclinical stages of Alzheimer's disease using the Lumipulse platform - PubMed
5 hours ago
- #Alzheimer's disease
- #Biomarkers
- #GFAP
- Study evaluates plasma GFAP's diagnostic performance in preclinical Alzheimer's disease using the Lumipulse platform.
- Research conducted in accordance with the Declaration of Helsinki, approved by the ethics committee of Hospital Universitario Marqués de Valdecilla.
- Authors report various conflicts of interest, including advisory roles and consultancy for pharmaceutical companies.
- References include key studies on Alzheimer's disease biomarkers and diagnostic criteria.